Manager TitleAgeSince
Chief Operating Officer - 27/08/2025
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer 57 04/08/2024
Date Insider Type Main position Quantity % Market Cap. Importance
29/08/25 Tender

Chief Technology Officer

222,423 0.5811%
29/08/25 Tender

Chief Executive Officer; Director

1,106,638 2.8914%
29/08/25 Tender

Chief Operating Officer

578,671 1.5119%
Change 5-day change 1-year change 3-year change Capi.($)
+0.20%-0.39% - - 449M
-2.69%-5.28%+58.42%+65.89% 68.45B
-0.92%+7.67%+14.26%+90.92% 61.31B
0.00%+0.39%+20.52%+98.45% 55.73B
-0.41%+1.78%+12.44%+108.30% 47.51B
-1.77%-2.06%+19.09%+37.46% 44.68B
-2.02%-10.77%+166.51%+773.18% 38.14B
+2.15%-0.47%+22.85%+56.09% 35.85B
-2.32%-2.24%+75.52%+52.70% 33.05B
+1.81%+5.03%-37.08%+402.76% 25.9B
Average -0.59%+2.41%+39.17%+187.31% 46B
Weighted average by Cap. -0.89%+2.25%+39.37%+160.89%
Logo iTeos Therapeutics, Inc.
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its EOS-984, a potentially first-in-class small molecule, focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1, a dominant transporter of extracellular adenosine, expressed on intratumoral T cells, which allows adenosine entry into the cell, disturbing T cell metabolism, expansion, effector function, and survival. It is also developing EOS-215, a potential best-in-class monoclonal antibody which antagonizes the triggering receptor expressed on myeloid cells 2.
Employees
173
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. ITOS Stock